A recent study posted to Research Square* preprint server evaluated the neutralizing antibody titers against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant and its ...
NVX-CoV2373 (marketed as Nuvaxovid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine Protein-based vaccines have a long ...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1–2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback